A high performance liquid chromatography -tandem mass spectrometry (LC-MS/MS) 21 method, using hydrophilic interaction liquid chromatography (HILIC) 22 chromatography for the analysis of fosfomycin in human plasma and urine, has been 23 developed and validated. The plasma method uses a simple protein precipitation 24 using a low volume sample (10 μL) and is suitable for the concentration range of 1 to 25 2000 μg/mL. The urine method involves a simple dilution of 10 μL of sample and is 26 suitable for a concentration range of 0.1 to 10 mg/mL. The plasma and urine results, 27 reported respectively, are for recovery (68, 72%), inter-assay precision (≤9.1%, 28 ≤8.1%) and accuracy (range -7.2 to 3.3%, -1.9 to 1.6%), LLOQ precision (4.7%, 3.1%) 29 and accuracy (1.7% and 1.2%), and includes investigations into the linearity, stability 30 and matrix effects. The method was used in a pilot pharmacokinetic study of a 31 critically ill patient receiving IV fosfomycin, which measured a maximum and 32 minimum plasma concentration of 222 μg/mL and 172 μg/mL, respectively, after the 33 initial dose, and a maximum and minimum plasma concentration of 868 μg/mL and 34 591 μg/mL, respectively, after the fifth dose. The urine concentration was 2.03 35 mg/mL after the initial dose and 0.29 mg/mL after the fifth dose.  This is the first method published that is suitable for the quantification of 47 fosfomycin in both plasma and urine. 48
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and accuracy (1.7% and 1.2%), and includes investigations into the linearity, stability 30 and matrix effects. The method was used in a pilot pharmacokinetic study of a 31 critically ill patient receiving IV fosfomycin, which measured a maximum and 32 minimum plasma concentration of 222 μg/mL and 172 μg/mL, respectively, after the 33 initial dose, and a maximum and minimum plasma concentration of 868 μg/mL and 34 M a n u s c r i p t 6 source interface operating in negative-ion mode was used for the multiple reaction 108 monitoring (MRM) LC-MS/MS analysis. MS conditions for FOM and the internal 109 standard (IS; EPA) are reported in Table 1 . The interface settings consisted of the 110 nebulizing gas flow of 3 L/min, a de-solvation line temperature of 250°C, heat block 111 temperature of 400°C and a drying gas flow of 15 L/min. 112
The compounds were separated on a Merck SeQuant zic-HILIC, 2.1 x 50 mm, 5.0 μm 113 analytical column (operated at 24° C) protected by a 20 mm SeQuant zic-HILIC 114 guard cartridge using an isocratic mobile phase containing acetonitrile with 2 mM 115 ammonium acetate, pH 4.8 (85/15 v/v) at a flow rate of 0.3 mL/min. The injection 116 volumes used were 0.1 μL for the plasma assay and 0.5 μL for the urine assay. The 117 retention time for both FOM and EPA was 2.5 min. 118 2.3. Stock and standard solution preparation 119 2.3.1. Standards for plasma analysis 120
Aqueous stock solutions for plasma standard preparation (at 1, 2 and 10 mg/mL) 121 were stored at -80°C. On the day of assay these were diluted with drug free plasma 122 to yield calibration standards from 1 to 2000 µg/mL that was processed alongside 123 the clinical samples. 124
Standards for urine analysis 125
Aqueous stock solutions for urine standards of FOM (2, 5, 10, and 50 mg/mL) were 126 stored at -20°C. On the day of assay these were diluted with drug free urine to 127 prepare calibration standards from 0.1 to 10 mg/mL that were processed alongside 128 the clinical samples. 129
Internal standard solution 130
Ethylphosphonic acid (EPA) in acetonitrile was used as internal standard for the 131 plasma assay (10 µg/mL), and an aqueous EPA solution was used as internal standard 132 for the urine assay (1 mg/mL). Solutions were stored at -20°C.M a n u s c r i p t 7 2.3.4. Quality Controls 134 Quality controls were prepared by spiking drug free plasma with FOM to 135 concentrations of 3, 800 and 1600 µg/mL, and stored at -80°C until assay. On the day 136 of assay an additional QC at 80 µg/mL was prepared by diluting with blank plasma 137 the QC at 800 µg/mL. The four sets of QCs were assayed alongside clinical samples. 138
Quality controls for urine analysis were prepared at FOM concentrations of 0.3, 2 139 and 8 mg/mL. The urine QCS were stored at -20°C until assayed alongside clinical 140 samples. For both plasma and urine the concentration of each clinical sample was obtained 155 using the data from the calibration curve prepared (in either plasma or urine) within 156 the batch using a quadratic regression with peak-area ratio (drug/internal standard 157 area responses) against concentration (x), with a 1/x 2 weighting as the mathematical 158 basis of the quantification. 159
A c c e p t e d M a n u s c r i p t 8
Validation 160
The validation was performed in accordance with the guidelines provided by the US 161
Food and Drug Administration (USFDA) and met the criteria required to demonstrate 162 the method is suitable for intended purpose [23] . The validation for both plasma and 163 urine was assessed for matrix effects, lower limit of quantification (LLOQ), linearity, 164 inter-day precision and accuracy, freeze-thaw stability of quality control samples and 165 the stability of standard solutions. 166 2.5.1. Limit of quantification 167
The lower limits of quantification for FOM were evaluated by analysis of replicate 168 standards, for both plasma and for urine samples. 169
Linearity 170
To investigate linearity, calibration curves were prepared using the corresponding 171 concentration ranges suitable for each matrix. 
Pharmacokinetic application 207
The method was developed for the analysis of plasma and urine samples from a 208 pharmacokinetic study with critically ill patients receiving an intravenous dose of 6 g 209 of FOM every 6 hours with expected peak plasma concentrations of around 200 210 µg/mL, an expected plasma half-life of 2 h, and urinary concentrations of around 5 211 mg/mL [25] . 212
One critically ill patient was administered an intravenous dose of 6 g fosfomycin 213 disodium. Blood samples (3 mL) were taken prior to dosing (0 h) and 0.5, 0.75, 1, 1.5, 214 2, 4, and 6 h post administration using heparinized vacuum tubes (Greiner Bio-One, This isocratic method uses a low ionic strength of 2 mM ammonium acetate buffer in 249 85% acetonitrile which has been reliable and provided consistent results with 250 minimal loss to chromatographic shape and reproducibility. Regenerating the 251 column after every 300 -400 injections of samples, particularly the urine samples, 252 and keeping buffer concentration to as low an ionic strength as possible, was 253 advantageous to long term use. Using a guard column extended the column life but 254 as the separation is highly dependent on the salt concentration and its impact on the 255 stationary phases aqueous-rich layer, the regeneration of the column was critical to 256 maintaining the quality of chromatography. 257
Another aspect of the method development that was found to affect both the 258 chromatographic retention and peak shape was the injection volume and the 259 composition of the sample being injected. Despite the low injection volumes being 260 used, 0.1 μL for plasma and 0.5 μL for urine, we conclude that the changes in the 261 quality of the chromatography observed were due to the sensitivity of the 262 interaction of FOM with the stationary phase from changes in ionic strength and pH 263 of the buffer [26, 27] . For the development of a bio-analytical assay using HILIC 264 chromatography, consideration of the organic to aqueous ratio, concentration of 265 salts, and finally, the presence of acids or base, is required. A dilution with plasma 266 was used in the plasma method as the ratio of acetonitrile to aqueous concentration 267 had an impact on the quality of the chromatographic peak shape and retention; the 268 concentrations found in clinical samples from the pilot study allowed this dilution. 269
The urine method included a dilution of sample that improved the chromatographic 270 separation by either reducing the presence of endogenous salts in the sample or 271 controlling the pH. 272 Buszewski [26] and Alpert describe the mechanism of HILIC separation as being 273 based on an interplay of a partitioning equilibrium in the aqueous layer (based on 274 the hydrophilicity of the analyte), weak electrostatic mechanisms, and dipole-dipole 275 interactions (including hydrogen-bonding) [29] the impact of each parameter on theM a n u s c r i p t 12 selectivity and reproducibility of chromatography requires a more sophisticated 277 management than in general reversed-phase chromatography, but which once 278 overcome can lead to a highly stable and robust method. 279
Validation 280
The LLOQ was determined as 1 μg/mL for plasma and 0.1 mg/mL urine with 281 precision calculated as 4.7 and 3.1%, respectively, and accuracy calculated as 1.7 and 282 1.2%, respectively ( Table 2 ). The signal to noise ratio of the lowest standard in the 283 calibration curve was 23.2 for plasma and 178 for urine and this data, combined with 284 the excellent precision and accuracy obtained at 1 μg/mL for plasma and 0.1 mg/mL 285 for urine, suggests substantial scope for achieving a lower LLOQ for both matrices 286 (see Figure A regression model with a weighted (1/x 2 ) quadratic curve provided the lowest 293 distribution of error across the substantial concentration range (1 to 2000 μg/mL for 294 plasma and 0.1 to 10 mg/mL for urine). The results of the linearity study are 295 described in Table 3 . 296
Precision and accuracy of the QC samples are shown in Table 4 for both plasma and 297 urine. All results were within the acceptance criteria of ± 15% of the nominal 298 concentration, indeed the results of all plasma QCs samples were within 9.1% and 299 urine within 4.2%. An incurred sample reanalysis was performed on a subset of 300 clinical samples and the results meet the current guidelines [23, 24] with >67% of 301 repeated results being within 30% of the mean. Indeed, 100% of the repeated results 302 were within 11%. 303
No signal suppression/enhancement was evident for either FOM or the internal 304 standard from the matrix study performed. The matrix effect evaluation is reported 305 in Table 5 . 306 M a n u s c r i p t 13 Despite using a very simple protein-precipitation for the extraction of FOM from 307 plasma the recovery was somewhat low at 68%. However, this extraction recovery is 308 not atypical for a drug with a highly hydrophilic nature due to preferential aqueous 309 partitioning. As was seen from the LLOQ testing, the variability was reliable 310 (precision 6.1%) and sensitivity (LLOD ca. 0.01 μg/mL) easily achievable. The recovery 311 of the internal standard EPA was good at 72% when tested at the undiluted 312 concentration of 10 μg/mL. The urine preparation was a simple dilution with internal 313 standard and as such provided recoveries of 98% when tested at 0.4 mg/mL. The 314 recovery results are reported in Table 5 . 315
Stock solution stability for FOM was tested for aqueous solutions stored for over 16 316 months at -80°C and for over 11 months at -20°C and it was found to be stable. FOM 317 was also found to be stable in plasma and urine across three freeze-thaw cycles 318 when stored at -80°C and thawed at ambient temperature in water (see Table 5 ). 319
Overall, the validation of this method was highly successful for both plasma and 320 urine with the method showing an excellent degree of reproducibility and accuracy, 321
and is suitable for use in the analysis of patient samples in a pharmacokinetic study. 322
This technique offers a simple and robust method for the analysis of FOM in both 323 plasma and urine in patient samples. Other quantitative methods have been 324 described for the determination of FOM in serum or plasma [10, 12, 14, 15, 20, 22 ] 325 and urine [11] . However, these methods often require a significant amount of time 326 in sample preparation or technique, and none offer a chromatographic system 327 suitable for a pharmacokinetic study of FOM in both plasma and urine. 328
Pharmacokinetic analysis 329
The plasma concentration-time profile obtained in the pilot pharmacokinetic study is 330 shown in Figure 4 . The peak plasma concentration in this patient after receiving the 331 initial dose was 222 µg/mL, and the trough concentration was 141 µg/mL. Increased 332 plasma concentrations were observed after receiving the fifth dose of FOM, with the 333 peak plasma concentration recorded as 868 µg/mL, and the trough concentration 334 was 592 µg/mL. The urinary concentration determined from a 6 h sample takenM a n u s c r i p t 14 post-dose and was 2.03 mg/mL after the initial dose and 0.29 mg/mL after the fifth 336 dose of FOM. 337
Conclusion

338
The developed analytical method is a sensitive, simple and robust tool to analyse 339 FOM in plasma and urine of patients. With the increasing prevalence of MDR 340 organisms and the reduced effectiveness of currently available antibiotics this 341 method allows the opportunity to study the disposition of FOM, particularly in at-risk 342 patient groups. This research may improve dosing strategies which could minimize 343 the risk of increasing resistance and bring an effective antibiotic back into the hands 344 of treating physicians. 345 M a n u s c r i p t 7.8 mg /mL 8.2 4.4 1.0 a matrix factor: calculated as a ratio of peak area of FOM in the presence of matrix to the peak area in 360 the absence of matrix (normalized using the internal standard). 361 362 M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t 
